BamSEC and AlphaSense Join Forces
Learn More

Nektar Therapeutics

NASDAQ: NKTR    
Share price (12/20/24): $0.93    
Market cap (12/20/24): $171 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1(6)
from 10-Q 17 pages Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan
12/34/56
EX-10.1(6)
from 10-Q 5 pages Amendment No. 1 to Purchase and Sale Agreement
12/34/56
EX-10.1
from 8-K 31 pages Nektar Therapeutics Securities Purchase Agreement Agreement
12/34/56
EX-10.6
from 10-Q 10 pages Certain Confidential Information Contained in This Document, Marked by [***], Has Been Omitted Because It Is Not Material and Is the Type That the Registrant Treats as Private or Confidential
12/34/56
EX-10.2
from 10-Q 16 pages Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan
12/34/56
EX-10.1
from 10-Q 9 pages Employment Separation and Release Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Confidential Consulting Agreement
12/34/56
EX-10.2
from 10-Q 14 pages Employment Transition, Separation and Consultation Agreement
12/34/56
EX-10.1
from 10-Q 14 pages Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan
12/34/56
EX-10.40
from 10-K 10 pages Amendment No. 2 to Strategic Collaboration Agreement
12/34/56
EX-10.1
from 10-Q 16 pages Nektar Therapeutics Amended and Restated 2017 Performance Incentive Plan
12/34/56
EX-10.39
from 10-K 70 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Purchase and Sale Agreement Dated as of December 16, 2020 Between Nektar Therapeutics and Healthcare Royalty Partners IV, L.P., Hcrp Overflow Fund, L.P., Hcr Stafford Fund, L.P., Hcr Potomac Fund, L.P., and Hcr Canary Fund, L.P. and Hcr Collateral Management, LLC, Solely in Its Capacity as Purchaser Representative [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed
12/34/56
EX-10.35
from 10-K 82 pages [***] Certain Information in This Document Has Been Omitted From This Exhibit Because It Is Both (I) Not Material and (II) Would Be Competitively Harmful if Publicly Disclosed. Co-Development Agreement
12/34/56
EX-10.2
from 10-Q 12 pages Material contract
12/34/56
EX-10.1
from 10-Q 17 pages Material contract
12/34/56
EX-10.1
from 10-Q 4 pages Amended and Restated Compensation Plan for Non-Employee Directors -1
12/34/56
EX-10.35
from 10-K 25 pages Material contract
12/34/56
EX-10.19
from 10-K 7 pages Material contract
12/34/56
EX-10.17
from 10-K 19 pages Material contract
12/34/56
EX-10.1
from 10-Q 8 pages Separation, Consulting and General Release Agreement Recitals
12/34/56